Asia One1d
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...
Finanznachrichten38m
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad ...
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend Insights - Technavio
Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 ...
pharmaphorum1d
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...
Morningstar5d
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ --BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License ...
GEN14h
Alzheimer’s Drug Shows Slower Cognitive Decline in Lower Tau Patients
After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.
Seeking Alpha4d
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Japanese drugmaker Eisai (OTCPK:ESAIY) (OTCPK:ESALF), Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, Leqembi, has completed the rolling submission of a Biologics License ...
The Pharma Letter4d
BRIEF—Eisai completes rolling submission to US FDA for Leqembi maintenance dosing
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) ...